ASH22
Shambavi Richard, discusses a retrospective study on extramedullary disease and CAR-T in multiple myeloma.
Advertisement
Simona Soverini, PhD, discusses new molecular data on CML, remaining challenges, and potentially practice-changing data.
Sarah Tasian, MD, of the Children's Hospital of Philadelphia, talks with The HemOnc Pulse about pediatric oncology.
A simulation approach identified odronextamab dosing regimens that could be used in children with aggressive NHL.
Advertisement
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Patients with ALL who underwent allogeneic HSCT in their first complete remission had a two-year OS rate of 73.9%.
Cachexia could be used as a prognostic marker for survival after CAR-T therapy in patients with aggressive B-cell lymphoma.
In follow-up data from the phase II CAPTIVATE study, ibrutinib plus venetoclax demonstrated a favorable benefit-risk profile.
An asparaginase-containing, pediatric-inspired regimen led to an overall survival benefit in teens and young adults with ALL.
Zanubrutinib may be “more efficacious and better tolerated” than ibrutinib for patients with relapsed/refractory CLL or ...
Amy Kirkwood, MSc, discusses results from the randomized phase III UKALL trial during the 2022 ASH Annual Meeting.
SOHO President Jennifer R. Brown, MD, PhD, speaks about the phase III ALPINE study, which compared BTK inhibitors in CLL/SLL.
The CLL2-Give trial determined that obinutuzumab, ibrutinib, and venetoclax is a “potent and promising” treatment for ...
Srdan Verstovsek, MD, discusses using machine learning to predict resistance to hydroxyurea therapy in polycythemia vera.
Patients with chronic lymphocytic leukemia (CLL) primarily rely on their physicians for information about their disease.
Patients with MPN have a high risk of death from cardiovascular causes.
Patients with MPN who are employed face a “high economic burden,” especially if they experience thrombotic events.
Statin use may reduce the risk of developing a myeloproliferative neoplasm (MPN), according to a recent study.
Chadi Nabhan, MD, MBA, FACP, interviews Srdan Verstovsek, MD, on highlights in MPN research at the 2022 ASH Annual Meeting.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
670 Madison Ave.
Manalapan, NJ 07726